Healthcare Sales & Marketing Network News: peripheral neuropathic pain

Searching News Database: peripheral neuropathic pain

HSMN NewsFeed - 24 May 2021
Eliem Therapeutics Announces $60 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 14 Nov 2018
Gr�nenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 31 Aug 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
Biopharmaceuticals

HSMN NewsFeed - 30 Jun 2017
Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2016
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 7 Sep 2016
BlueWind Medical Announces CE-Mark for the BlueWind VIVENDI(TM) Miniature Implanted Wireless Stimulator to Treat Peripheral Pain
Devices Neurology Regulatory

HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Aug 2012
Astellas Pharma Europe Ltd. Appoints Dr Susan Wood as Senior Director, Market Access
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jan 2012
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2011
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2011
NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Apr 2011
NeurogesX CEO Anthony DiTonno to Retire by Year End
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Nov 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 19 Nov 2010
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
Biopharmaceuticals Drug Delivery Reimbursement

HSMN NewsFeed - 3 Feb 2010
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 1 Dec 2009
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Nov 2009
NeurogesX Expands Commercial Operations Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Biopharmaceuticals

HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jun 2009
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
Biopharmaceuticals Drug Delivery Distribution

HSMN NewsFeed - 10 Jun 2009
NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 21 May 2009
NeurogesX Receives European Commission Approval for Qutenza(TM)
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 29 Apr 2009
Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2009
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
Biopharmaceuticals Pain Management Regulatory

HSMN NewsFeed - 30 Jan 2009
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Biopharmaceuticals

HSMN NewsFeed - 18 Nov 2008
Impax Sued Based on Anda for Generic Cymbalta(R)
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals

HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals

HSMN NewsFeed - 18 Jan 2008
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Biopharmaceuticals

HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Oct 2007
NeurogesX Expands Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2007
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 5 Sep 2007
NeurogesX Appoints New Director to the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Sep 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Biopharmaceuticals Pain Management

HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2007
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2007
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2007
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
Biopharmaceuticals

HSMN NewsFeed - 29 May 2007
NeurogesX Appoints BioMarin CEO Bienaime as Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals

HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Sep 2006
Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
Biopharmaceuticals

HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Mar 2006
Pfizer's Lyrica Approved for the Treatment of Generalized Anxiety Disorder (GAD) in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Mar 2006
Study Suggests Cymbalta(R) Significantly Reduces Core Anxiety Symptoms of Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 15 Feb 2006
Eli Lilly and Company and Boehringer Ingelheim Announce Changes to Their Contractual Agreements for Yentreve(R)/AriClaim(R)
Biopharmaceuticals

HSMN NewsFeed - 14 Feb 2006
Study Finds Cymbalta(R) Was As Safe And Well-Tolerated As Routine Drug Treatments For Diabetic Nerve Pain
Biopharmaceuticals

HSMN NewsFeed - 27 Jan 2006
Pfizer's Lyrica Receives Positive Opinion From CHMP for the Treatment of Generalized Anxiety Disorder in Adults
Biopharmaceuticals Regulatory

Return to NewsFeed

Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 18 additional stories matching:
peripheral neuropathic pain
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.